Evaluation of safety in biomarker driven multiple agent phase IB trial

Motomi Mori, Racky Daffé, Byung S. Park, Jeffrey Tyner

Research output: Chapter in Book/Report/Conference proceedingChapter


Tyner and colleagues in the Center for Hematological Malignancies, Knight Cancer Institute, at the Oregon Health & Science University have recently developed a novel kinase-inhibitor assay and rapid mutation screening to identify molecularly targeted drugs to which patient leukemic cells are sensitive. As a proof of concept and feasibility trial, they proposed a phase IB trial focusing on feasibility and safety of an assay-based kinase-inhibitor treatment assignment in combination with the standard induction chemotherapy among newly diagnosed acute myeloid leukemia patients. Because each patient receives one of five kinase inhibitors in combination with standard chemotherapy, the sample size for each kinase inhibitor group is varied and limited. In addition, there is a different toxicity profile associated with each inhibitor, making safety assessment challenging. We will discuss a continuous toxicity monitoring plan in biomarker driven, multiple agent feasibility and safety trials, and evaluate its operating characteristics in a simulation study.

Original languageEnglish (US)
Title of host publicationFrontiers of Biostatistical Methods and Applications in Clinical Oncology
PublisherSpringer Singapore
Number of pages12
ISBN (Electronic)9789811001260
ISBN (Print)9789811001246
StatePublished - Oct 3 2017


  • Continuous toxicity monitoring
  • Early phase clinical trials
  • Multi-drug trials
  • Phase I oncology trials
  • Precision medicine
  • Safety evaluation

ASJC Scopus subject areas

  • Medicine(all)
  • Mathematics(all)
  • Social Sciences(all)


Dive into the research topics of 'Evaluation of safety in biomarker driven multiple agent phase IB trial'. Together they form a unique fingerprint.

Cite this